Evotec AG (NASDAQ:EVO) Short Interest Up 36.3% in February

Evotec AG (NASDAQ:EVO) was the target of a significant increase in short interest in February. As of February 27th, there was short interest totaling 352,335 shares, an increase of 36.3% from the February 12th total of 258,431 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily volume of 112,820 shares, the short-interest ratio is presently 3.1 days. Based on an average daily volume of 112,820 shares, the short-interest ratio is presently 3.1 days. Currently, 0.1% of the company’s stock are short sold.

Institutional Investors Weigh In On Evotec

Several hedge funds have recently bought and sold shares of the stock. Valeo Financial Advisors LLC bought a new stake in shares of Evotec during the second quarter worth approximately $43,000. BNP Paribas Financial Markets grew its position in shares of Evotec by 62.2% in the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after purchasing an additional 4,600 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after purchasing an additional 9,289 shares during the period. Marshall Wace LLP bought a new position in shares of Evotec during the fourth quarter worth approximately $40,000. Finally, Thrivent Financial for Lutherans acquired a new stake in Evotec during the 3rd quarter worth approximately $53,000. 5.81% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Berenberg Bank assumed coverage on shares of Evotec in a research report on Tuesday, February 3rd. They set a “buy” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Evotec in a report on Monday, December 29th. Finally, Wall Street Zen raised Evotec from a “sell” rating to a “hold” rating in a research report on Saturday, January 10th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $7.00.

Evotec Price Performance

Shares of NASDAQ EVO traded down $0.10 during mid-day trading on Friday, reaching $2.31. 152,215 shares of the company were exchanged, compared to its average volume of 175,397. The company’s 50-day simple moving average is $3.43 and its 200-day simple moving average is $3.44. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.03 and a current ratio of 2.12. Evotec has a twelve month low of $2.31 and a twelve month high of $4.80.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.